Home/Pipeline/Zorevunersen (STK-001)

Zorevunersen (STK-001)

Dravet Syndrome

Phase 3Active

Key Facts

Indication

Dravet Syndrome

Phase

Phase 3

Status

Active

Company

Stoke Therapeutics

About Stoke Therapeutics

Stoke Therapeutics is developing a new category of RNA medicines focused on upregulating protein expression from functional genes to treat severe genetic diseases. The company's lead program, zorevunersen (STK-001), is in Phase 3 for Dravet syndrome, with recent data published in The New England Journal of Medicine demonstrating potential disease modification. Stoke's strategy leverages its proprietary TANGO platform to address haploinsufficiency disorders, a large class of genetic conditions, and expand into other areas of high unmet medical need. Its $1.91B valuation reflects significant investor confidence in this novel therapeutic approach.

View full company profile

Therapeutic Areas

Genetic Epilepsy Optic Nerve Disorders Neurodevelopmental Disorders

Other Dravet Syndrome Drugs

Drug	Company	Phase	Status
BL-001	Bloom Science	Phase 2 (Planned)	Active
Cannabidiol Program	Nexien BioPharma	Pre-clinical	Active
RT101	Regel Therapeutics	Preclinical	Active
ETX101	Encoded Therapeutics	Phase 3	Active
EPX-100 (clemizole)	Harmony Biosciences	Phase 1/2	Active